GIST pipeline
What is next, and who is running it?
The next dated milestone on each program. A hollow marker is a registry primary completion date, not a company readout.
A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.
ClassNone selected
14 of 17 programs on this timeline
202520262027202820292030Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Today
Asan Medical Center 1
Rivoceranib + PaclitaxelPhase 2
Registry, Aug 31, 2027
Ascentage Pharma 1
Olverembatinib (HQP1351)Phase 3
Registry, Mar 31, 2027
Bayer 1
RegorafenibApproved
No dated milestone in 2025 to 2030
Blueprint Medicines 1
AvapritinibApproved
No dated milestone in 2025 to 2030
Centre Leon Berard 1
Atezolizumab + ImatinibPhase 2
Registry, Oct 2027
Cogent Biosciences 1
No dated milestone in 2025 to 2030
Deciphera Pharmaceuticals 2
RipretinibApproved
Registry, Dec 2027
DCC-3009Phase 1/2
Registry, May 2028
GSK 1
Registry, Mar 10, 2027
Merck 1
BelzutifanPhase 2
Registry, Nov 18, 2032
Ningbo Newbay Technology Development 1
NB003Phase 2/3
Registry, Aug 2028
Novartis 1
ImatinibApproved
No dated milestone in 2025 to 2030
Peking University 1
Envafolimab + RegorafenibPhase 2
Registry, Jul 30, 2027
Pfizer 1
SunitinibApproved
No dated milestone in 2025 to 2030